The overall purpose of this study is to estimate prospectively the risks of breast, ovarian, and other cancers in BRCA1 and BRCA2 (BRCA1/2) carriers and to assess lifestyle and genetic factors that may modify cancer risks. Additionally, we aim to create a prospective registry of gene carriers for potential use in future clinical trials.
Currently, there are 15 European centers participating and we have prospective data collected on ~14,000 female and male BRCA1 and BRCA2 mutation carriers.
The data for the IBCCS is collected at different centers in 15 countries. Overall coordination is through the Netherlands Cancer Institute. Research at the Netherlands Cancer Institute is supported by institutional grants of the Dutch Cancer Society and of the Dutch Ministry of Health, Welfare and Sport. The individual participating centers and studies of the IBCCS are supported by a number of research grants. The Dutch HEBON study is supported by the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, NKI2007-3756, NKI 12535, the Netherlands Organisation of Scientific Research grant NWO 91109024, the Pink Ribbon grants 110005 and 2014-187.WO76, the BBMRI grant NWO 184.021.007/CP46, and the Transcan grant JTC 2023 Cancer 12-054.